GlassScriptPhysician profile
Christopher Peter Thibeault
NPI 1205487493
$1,736.55
in general payments reported to CMS, 2019-2025
20 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.27 · 2023: $81.41 · 2024: $298 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,720.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $450.76 | 2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $333.29 | 2023-2025 | Onpattro, Amvuttra |
| Edwards Lifesciences Corporation | $160.01 | 2025 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $103.71 | 2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.41 | 2024-2025 | Lifevest |
| Amgen INC. | $89.46 | 2024-2025 | Repatha |
| Merck Sharp & Dohme LLC | $80.98 | 2024-2025 | Verquvo, Capvaxive |
| Daiichi Sankyo INC. | $78.94 | 2024-2025 | Injectafer |
| Novartis Pharmaceuticals Corporation | $66.64 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $56.36 | 2023-2024 | Inpefa |
| Angiodynamics, INC. | $38.88 | 2025 | Alphavac |
| Philips North America LLC | $37.49 | 2024-2025 | (Ck4) Mcot, Mcot |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.50 | 2023 | Jardiance |
| Boston Scientific Corporation | $20.67 | 2025 | Enroute Transcarotid Stent |
| Baxter Healthcare | $20.06 | 2024 | Hillrom - Carnation Ambulatory Monitor |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $19.43 | 2023 | Andexxa |
| Bridgebio Pharma, INC. | $16.30 | 2025 | Attruby |
| Genentech USA, INC. | $16.27 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.82 | 2025 | |
| Chiesi USA, INC. | $13.57 | 2023 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Thibeault listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.